Literature DB >> 14618560

Should titration schedules for cholinesterase inhibitors be changed?

Sudip Sikdar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14618560     DOI： 10.1002/gps.996

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN： 0885-6230            Impact factor:   3.485


× No keyword cloud information.
  3 in total

Review 1.  Transdermal delivery of treatment for Alzheimer's disease: development, clinical performance and future prospects.

Authors:  Agnes L F Chan; Yie W Chien; Shun Jin Lin
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

2.  Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease.

Authors:  Howard H Feldman; Roger Lane
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-03-12       Impact factor: 10.154

3.  Safety/Tolerability and efficacy of rivastigmine in taiwanese patients with Alzheimer's disease: a prospective post-marketing surveillance study.

Authors:  Pai-Yi Chiu; Dao-En Dai; Hai-Pei Hsu; Chao Lee; Juei-Jueng Lin; Hung-Chou Kuo; Ying-Chih Huang; Yung-Chang Liu; Ching-Piao Tsai
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.